Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Three years after creating its RX-04 discovery platform, Rib-X Pharmaceuticals Inc. has vetted 1,400 compounds, tuned them for efficacy against multi-drug resistant bacteria, and is in the process of selecting a handful of candidates to prep for an IND in 2012.
You may also be interested in...
Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.